

Technology Assessment of Next Generation Sequencing in Personalized Oncology

ZorgInstituut Nederland 01-11-2018

Edwin Cuppen, hoofdaanvrager Valesca Retèl, projectleider



Rationale

- Large variability of sequencing/NGS tests in the Netherlands
- Increased use of immunotherapy, while this is effective for only a small part of the patients
 - Consequences:
 - 个Toxicities
 - ↓QoL
 - ↑Health care costs





ZonMW GGG ronde Personalized Medicine


RQ: How can we optimize the use of NGS in the Netherlands?



HTA-network meets CPCT










<u>TA</u>NGO

Technology Assessment

HTA: broad evaluation of new or existing health technologies

- -Clinical effectiveness
- -Financial (cost-effectiveness)
- -Patient related
- -Ethical/legal
- -Organizational
- → Information for policy making
 → Decision making for groups of patients






TA<u>NGO</u>


Next Generation Sequencing in Oncology

- Tests for all relevant mutations in 1 experiment
- To prescribe the most optimal therapy
- This could improve survival with less toxicity
- Assist in controlling healthcare costs :
- → Offering (often expensive) treatment to only those likely to benefit.






Center for Personalized Cancer Treatment (CPCT)





Early HTA



-little data available
-technology still dynamic - "it is always too early, when it is suddenly too late"
-adoption limited

-> anticipation!




Purpose TANGO

A) to <u>expand molecular profiling</u> of tumors in order to <u>improve immune- and targeted treatment</u> selection and outcomes in patients with advanced NSCLC (and melanoma)

B) to <u>project long-term cost-effectiveness</u>, budget impact, and relevant patient & organizational issues related to the introduction of WGS compared to standard diagnostics.




Timeline






Clinical pathway NSCLC






Workpackages





Patient pathway (micro level)




- WP1 diagnostic pathway
- WP2 diagnostics + treatment + survival
- WP3,4 diagnostics + treatment longer FU, costs, QoL




System level

WP4,5,6





Patient pathway (micro level)



- WP1 diagnostic pathway
- WP2 diagnostics + treatment + survival
- WP3,4 diagnostics + treatment longer FU, costs, QoL



Standard diagnostics vs WGS

• Analysis standard diagnostics results vs WGS

-number of targets

-type of targets

-costs

• Organization Molecular Tumor boards (in collaboration with PATH project)



Costs of diagnostics

• Costs WGS (HMF)

- based on microcosting
- Costs current diagnostics with total diagnostic pathways (ZA codes)
 - UMCU
 - NKI-AVL
 - Rijnstate
- Linkage IKNL and PALGA data nationwide (NZa)



Prelim: Range of standard diagnostics


Table X

Microcosting current (molecular) diagnostic techniques and whole genomesequencing.

					Process-bas	ed cost calcu	lations (r	noleculai	[.]) diagnostic t	echniqu	ies	_		
		Single/panel												wgs
		FISH /					Sanger							
Components cost calculations	ІНС	CISH	RT-PCR	HRM	GeneScan	MassArray	seq	NGS	Therascreen	Cobas	Biocartis	XX	xxx	WGS
Base case														
ххх														
Capital costs														
ххх														
Maintenance costs														
ххх														
Software (ICT) costs														
ххх														
Operational costs														
ххх														
Total costs per tumor normal / per														
patient	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx	€ xxx



Patient pathway (micro level)



- WP1 diagnostic pathway
- WP2 diagnostics + treatment + survival
- WP3,4 diagnostics + treatment longer FU, costs, QoL



Status CPCT-02

		2016								2017											2018												
	04	05	06	07	08	09	10	11	12	01	02	03	04	05	06	07	08	09	10	11	12	01	02	03	04	05	06	07	08	09	10	11	٤2
Included/month	3	6	5	2	6	7	7	8	9	9	6	15	9	6	16	10	7	8	18	18	12	21	20	22	18	24	28	15	7	9	5	0	0
Included/year	53						134										169																
Sequenced/month	3	2	3	2	3	5	5	8	4	6	4	12	5	5	8	7	1	7	9	11	9	12	13	11	15	17	22	5	4	5	2	0	0
Sequenced/year					35										8	4											1	06					
Sequenced + Immuno/month	3	1	2	1	1	0	0	2	2	1	0	7	1	2	2	5	1	3	2	3	5	4	5	3	6	4	9	3	1	1	0	0	0
Sequenced + Immuno/year					12										3	2											(1)	6					
Included																	356	j															
Sequenced								225																									
Sequenced + Immuno																	80																




Statistical plan (WP1+2)

Confirmation findings biomarker by:

- -Literature
- -Larger sample
- -Longer FU
- -Clinical validation
- -> e.g. Simon 2-stage design?



Patient pathway (micro level)



- WP1 diagnostic pathway
- WP2 diagnostics + treatment + survival
- WP3,4 diagnostics + treatment longer FU, costs, QoL




Long term survival from various databases

	CPCT-02	DMTR	SANTEON	NVALT	IKNL
	amendment				
	questionnaires				
QoL	Х				
utility	Х				
Productivity	Х				
Informal care	Х				
Patient characteristics	Х	Х	Х	Х	Х
Tumour characteristics		Х	Х	Х	Х
Treatment type					
Targeted therapy	Х	X		Х	Х
Immunotherapy	Х	Х		Х	Х
Chemotherapy	Х	X	Х	Х	Х
other	Х	Х			Х
Medicine type					
Targeted therapy		Х		Х	
Immunotherapy		X		Х	
Chemotherapy		X	Х		
other		Х			
OS		Х	Х	Х	Х
PFS		X		X	
Toxicity		X	Х	Х	
Performance score		X	Х	X	Х
Mutation type		Х		Х	
Risk factors		Х		Х	




Cost-effectiveness model: H-TArget model

Hybrid: decision tree (grey) + multi state model (blue)




Cost-effectiveness: "future value"






WP5: System dynamic model



International survey on the future of WGS

According to your expectations, will your institution use WGS in the future? What is / are the reason(s) that your institute will not be conducting or using WGS?





Scenario drafting (WP4&5)

 The turnaround time of WGS will in the next 5 years become equal to standard diagnostics

-> How likely is this scenario?

The costs for WGS will be twice as high as standard diagnostics

-> How likely is this scenario?


 WGS will be in routine practice as a diagnostic tool for advanced NSCLC

-> How likely is this scenario?



System level: WP6

WP4,5,6





Ethical & legal implications

• Focus on duty to recontact

 First legal framework, afterwards ethical focusgroups

First conclusion legal: no grounds for the existence of a "relative" duty

-> recommendation to prepare guideline



Planning

WP1	-finish costs standard diagnostics
	-analyze data for comparison SD & WGS
WP2	-analyze data for comparison SD & WGS
	-finish statistical plan
WP3	-analyze survival data from databases
	-tumor growth models
WP4	-analyze cost-effectiveness tumor-overarching
	-wider public benefits, scenario drafting
WP5	-analyze system dynamic model
	-scenario drafting
WP6	-finish legal papers
	-start patient and professional focus groups



Overall milestones


• Presentations

-CPCT-HMF symposium 2018

- Congress:
 - -Health-RI 2017
 - -SMDM: concept model TANGO HTA 2018
 - -Mini symposium TANGO 2018



Collaborations/networks





Acknowledgements



Collaborating hospitals & institutions













Dit project (846001002) wordt mogelijk gemaakt door

